CPL-01 in the Management of Postoperative Pain After Bunionectomy

Last updated: August 19, 2024
Sponsor: Cali Pharmaceuticals LLC
Overall Status: Active - Recruiting

Phase

3

Condition

Bunion

Treatment

Placebo

Local anesthetic injection of CPL-01

Naropin, 0.5% Injectable Solution

Clinical Study ID

NCT05831449
CPL-01-302
  • Ages 18-75
  • All Genders

Study Summary

Subjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ability to sign ICF

  • Bunion for elective primary unilateral, distal, first metatarsal bunionectomy withosteotomy and internal fixation under regional anesthesia, without collateralprocedures or additional surgeries

  • BMI ≤ 39 kg/m2

  • If biologically female, not pregnant or planning to become pregnant over the study

  • If biologically male, either sterile or using acceptable form of birth control

  • Be willing and able to complete study procedures

Exclusion

Exclusion Criteria:

  • Has previously undergone unilateral simple bunionectomy.

  • Has a planned concurrent surgical procedure

  • Has a concurrent painful condition that may require analgesic treatment during thestudy period or may confound postsurgical pain assessments

  • Has a history or clinical manifestation of significant medical, neuropsychiatric, orother condition that could preclude or impair study participation or interfere withstudy assessments.

  • Has a history of malignant hyperthermia or glucose-6-phosphate dehydrogenasedeficiency.

  • Has history or evidence of impaired liver function (e.g., alanine aminotransferase [ALT] > 3 × upper limit of normal [ULN] or total bilirubin > 2 × ULN), activehepatic disease, or cirrhosis.

  • Has history or evidence of impaired renal function (e.g., creatinine > 1.5 × ULN).

  • Has a history of malignancy in the past year

  • Has known or suspected daily use of opioids for 7 or more consecutive days withinthe previous 6 months

Study Design

Total Participants: 574
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 3
Study Start date:
May 22, 2023
Estimated Completion Date:
December 31, 2024

Study Description

After signing informed consent, subjects will be randomly assigned to receive study drug (either Investigational product, positive control, or negative control) during unilateral distal bunionectomy with osteotomy. Subjects will then remain at the hospital for 72-hours where pain and rescue medication usage will be assessed. Follow-up will then occur at 7 and 30 days afterwards.

The hypothesis is that subjects who receive CPL-01 will have less pain and require fewer opioids than subjects in the other two arms.

Connect with a study center

  • Todd Bertoch

    Salt Lake City, Utah 84101
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.